1. Home
  2. BNTC vs EBS Comparison

BNTC vs EBS Comparison

Compare BNTC & EBS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Benitec Biopharma Inc.

BNTC

Benitec Biopharma Inc.

N/A

Current Price

$7.92

Market Cap

315.4M

Sector

Health Care

ML Signal

N/A

Logo Emergent Biosolutions Inc.

EBS

Emergent Biosolutions Inc.

N/A

Current Price

$5.10

Market Cap

303.3M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
BNTC
EBS
Founded
1995
1998
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
315.4M
303.3M
IPO Year
2020
2006

Fundamental Metrics

Financial Performance
Metric
BNTC
EBS
Price
$7.92
$5.10
Analyst Decision
Strong Buy
Buy
Analyst Count
8
3
Target Price
★ $23.75
$10.00
AVG Volume (30 Days)
154.2K
★ 946.0K
Earning Date
11-13-2026
11-02-2026
Dividend Yield
N/A
N/A
EPS Growth
6.67
★ 125.83
EPS
★ N/A
N/A
Revenue
N/A
★ $742,900,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$7.03
P/E Ratio
★ N/A
N/A
Revenue Growth
★ N/A
N/A
52 Week Low
$7.89
$4.36
52 Week High
$14.39
$14.06

Technical Indicators

Market Signals
Indicator
BNTC
EBS
Relative Strength Index (RSI) 37.62 27.56
Support Level N/A $4.36
Resistance Level $13.87 $7.18
Average True Range (ATR) 0.66 0.42
MACD -0.08 -0.10
Stochastic Oscillator 5.18 3.79

Price Performance

Historical Comparison
BNTC
EBS

About BNTC Benitec Biopharma Inc.

Benitec Biopharma Inc is a clinical-stage biotechnology company focused on advancing novel genetic medicines. Its technology could provide a one-shot cure for a wide range of diseases that require strict, ongoing treatment regimens or have no effective treatment or only palliative care options. The Company is developing a silence-and-replace-based therapeutic (BB-301) for the treatment of Oculopharyngeal Muscular Dystrophy (OPMD), a chronic, life-threatening genetic disorder. The company has a single operating segment, which is the business of discovery and development of therapeutic agents for the treatment of genetic disorders.

About EBS Emergent Biosolutions Inc.

Emergent BioSolutions Inc offers public health products to the government and healthcare providers. Company operates in three segments namely Commercial Product, MCM Products, and Services segment. The Commercial Product Segment consisting of Nasal Spray; the MCM Products Segment consisting of Anthrax-MCM products, Smallpox-MCM products and Other Products and the Services Segment consisting of Bioservices portfolio. Geographically, the company operates in United States, Canada, and Others. It derives maximum revenue from United states. The company's products include: NARCAN Nasal Spray, KLOXXADO Nasal Spray, ACAM2000, ANTHRASIL, BAT, BioThrax, CNJ-016, raxibacumab injection, Ebanga, and others.

Share on Social Networks: